---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-019660"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-06-05T12:30:10+00:00"
generated_at: "2026-06-05T12:35:07.692166+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Moleculin announces strong physician intent to prescribe Annamycin in R/R AML; likelihood-to-prescribe score 6/7

## Summary
- Oncologists reported average likelihood-to-prescribe Annamycin of 6 out of 7, citing deep remissions and reduced cardiotoxicity.
- Physicians highlighted Annamycin's biomarker-agnostic applicability and potential to bridge patients to bone marrow transplant.
- Payers viewed Annamycin as a potentially valuable addition for R/R AML, driven by efficacy and safety profile.
- Key differentiators include MRD-negative responses and reduced cardiotoxicity, especially important for pediatric and repeat dosing.

## SEC filing metadata
- accession: 0001437749-26-019660
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-06-05T12:30:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926019660/0001437749-26-019660-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926019660/mbrx20260604_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-019660
- JSON: https://secwatch.observer/filing/0001437749-26-019660.json
- Plain text: https://secwatch.observer/filing/0001437749-26-019660.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.